Marwah M Albakri

Dr. Marwah M Albakri

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MAMarwah M Albakri
Marwah M Albakri
TP53 mutations drive oncogenesis and therapeutic resistance in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML), impairing p53-regulated functions such as apoptosis, immune surveillance, and genomic stability, leading to immune evasion and metabolic reprogramming. The tumor microenvironment in TP53-mutated MDS and AML fosters leukemic progression through cytokine dysregulation, altered metabolism, and immune suppression. Current therapies, including chemotherapy and hypomethylating agents, offer limited efficacy, resulting in poor overall survival rates for these high-risk patients. However, novel therapeutic approaches provide promising avenues, including MDM2 inhibitors, p53-reactivating agents, pathway-targeted inhibitors (Hedgehog, Wnt, NF-κB), immune modulation (checkpoint inhibitors, CAR-T therapy), metabolic interventions (fatty acid metabolism, glycolysis), and gene-editing technologies (CRISPR/Cas9, base editing). This review explores the mechanisms of immune dysfunction in TP53-mutated MDS and AML while highlighting emerging therapeutic strategies, emphasizing the integration of targeted, metabolic, and immune-modulating therapies as a transformative approach to improve patient outcomes.

10 October 2025 in Journal of Infection and Public Health
Verified
Journal Article
Open access
AKAiah Khateb
Aiah Khateb
ABAhmed Barefah
Ahmed Barefah
ZDZinab Doha
Zinab Doha
MAMarwah M Albakri
Marwah M Albakri
OROsman Radhwi
Osman Radhwi
Esam AzharEsam Azhar
Esam Azhar
Understanding the landscape of bloodstream infections (BSIs) in Lymphocytic leukemia patients with Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) is crucial for optimizing treatment and improving patient outcomes. This retrospective study investigated the prevalence and characteristics of BSIs in these patients diagnosed between 2008 and 2020 at King Abdulaziz University Hospital. Among 1488 patients, 72 cases of BSI were identified, with ALL being the predominant diagnosis (64 cases) and CLL (8 cases). A significant male bias was observed (53 males). Age distribution differed between ALL and CLL, with pediatric patients dominating ALL cases (49) while CLL was primarily diagnosed in the elderly (7 cases). Analysis of causative pathogens revealed a diverse spectrum. Bacterial infections were most prevalent (62 cases), followed by fungal (7 cases) and mixed bacterial-fungal infections (3 cases). Co-infection analysis identified frequent pairings like Staphylococcus with MRSA, E. coli with ESBL, and Klebsiella pneumoniae with Candida parapsilosis. CLL patients displayed a distinct infection pattern, with a higher prevalence of Streptococcus and Candida albicans. We observed differences in the prevalence of specific pathogens based on ALL or CLL diagnosis and remission state. Survival analysis indicated poorer outcomes with increasing age, highlighting the heightened risk associated with advanced age. Our findings emphasize the importance of tailoring infection management strategies based on patient demographics, diagnosis, and remission status for improved outcomes.